Why We Require a DEXA Scan Before Starting GLP-1 Therapy

If you walk into most weight-loss clinics in Dallas-Fort Worth and ask for semaglutide or tirzepatide, the workup is short — a few intake questions, a quick weight check, and a prescription. The scale will move. The number that matters most won't be measured.

At Highland Longevity, every patient who starts a GLP-1 medication for weight loss gets a DEXA body composition scan first. Not because we sell DEXA scans. Because without one, we don't actually know what we're treating — or what we're losing.

The Problem With "Just Lose Weight"

The bathroom scale is one of the worst tools in medicine. It tells you your total mass. It tells you nothing about what that mass is made of.

Two patients can both weigh 200 pounds. One might carry 30% body fat with healthy muscle reserves. The other might carry 42% body fat and already be sarcopenic — meaning they have clinically low muscle mass relative to what their frame and age call for. Same weight on the scale. Two completely different clinical situations. Two completely different treatment plans.

Now drop 30 pounds off each of them with semaglutide or tirzepatide. Did they lose mostly fat? Mostly muscle? Some mix? The scale can't answer that question. Neither can a BMI calculator. Neither can a tape measure.

Muscle Loss on GLP-1 Therapy Is a Real Clinical Concern

GLP-1 receptor agonists — semaglutide (the active molecule in the brand-name products Wegovy and Ozempic) and tirzepatide (the active molecule in Zepbound and Mounjaro) — work in part by reducing appetite and total caloric intake. Highland Longevity prescribes compounded semaglutide and tirzepatide and does not dispense the brand-name products. The molecule's mechanism is the same whether it's compounded or brand-name: that caloric deficit is what produces weight loss — and unfortunately, any rapid weight loss carries a risk of lean tissue loss alongside fat loss.

Published analyses of GLP-1 trial data have reported that lean mass can account for a meaningful share of total weight lost on these medications, with the exact percentage varying by study, patient population, and concurrent lifestyle factors. Lean mass is not just "muscle in the gym." It's also organ tissue, bone, and the structural muscle that lets a 65-year-old patient stand up from a chair without using their hands.

This isn't a reason to avoid GLP-1 therapy. These medications are some of the most effective tools we have for obesity, type 2 diabetes risk reduction, and cardiovascular risk reduction. It is a reason to manage them carefully — and you can't manage what you don't measure.

Why a Baseline DEXA Is Non-Negotiable

DEXA (dual-energy X-ray absorptiometry) is the clinical reference standard for body composition. In about ten minutes, a DEXA scan tells us:

• Total fat mass — how many pounds of fat you're actually carrying
• Total lean mass — muscle, organs, and structural tissue
• Visceral adipose tissue (VAT) — the metabolically active fat around your organs that drives most of the cardiovascular and metabolic risk
• Bone mineral density — important context as you lose weight
• Regional distribution — fat and muscle by limb and trunk, which matters for sarcopenia screening

That single set of numbers is the entire foundation of a defensible weight-loss plan. Without it, every later "you lost 25 pounds" conversation is missing the answer to the only question that actually matters: was that loss the kind of loss you wanted?

If we don't have a baseline DEXA on file, we have no objective way to confirm a year from now that your semaglutide or tirzepatide protocol delivered fat loss instead of muscle loss. We're guessing — and on a medication a patient may take for years, that's not good enough.

Why DEXA — But Not VO₂ Max — Before Weight Loss

One question that comes up often: "Do you also require VO₂ max testing before starting weight loss?" The answer is no.

DEXA and VO₂ max answer two completely different clinical questions:

• DEXA measures what your body is made of — fat, muscle, bone. It is directly relevant to what GLP-1 medications change. That's why we require it before starting therapy.
• VO₂ max measures how well your cardiovascular system delivers and uses oxygen. It is one of the strongest predictors of long-term mortality and a powerful tool for athletic performance and longevity programming — but it's not a prerequisite for safely prescribing a GLP-1 medication.

VO₂ max testing is a service we offer, and many of our longevity-focused patients elect to do it. But we don't gate weight-loss care behind it. That would create a barrier to treatment without changing how the GLP-1 protocol itself is run. Required workup should be tied to actual clinical decision-making — not bundled in to inflate the bill.

How We Use the DEXA Data

Once we have your baseline scan, the numbers feed three concrete parts of your plan:

1. Protein prescription

Your lean mass at baseline drives your daily protein target. Patients carrying lower lean mass — or those with sarcopenia risk on imaging — get more aggressive protein targets and earlier dietitian touch points. This isn't theoretical: protein intake is the single most controllable lever for preserving muscle during caloric deficit.

2. Resistance-training prescription

Patients starting a GLP-1 are not asked to "exercise more" in vague terms. Resistance training — not cardio — is the intervention that protects lean mass during weight loss, and your DEXA tells us how much priority it needs in your specific plan. Patients with already-low lean mass start a structured strength program before titration. Patients with healthy reserves get a less aggressive prescription.

3. Whether lean-mass-preserving protocols apply

For some patients — particularly older patients, post-menopausal women, and patients with low baseline lean mass — we may consider peptide protocols aimed at supporting lean mass during the rapid weight-loss phase. That decision is informed by the DEXA. We don't apply those protocols generically, and we don't apply them at all without a clear baseline.

A follow-up DEXA roughly 6 months into therapy then confirms whether the plan is working. If you've dropped 30 pounds and 27 of those pounds are fat, the protocol is working. If 12 of those 30 pounds are lean tissue, the plan needs to change — and we now have the data to change it deliberately, not by guesswork.

What This Looks Like in Practice

Most weight-loss clinics treat a GLP-1 medication as the product. The visit is built around getting the prescription out the door. Body composition isn't measured because the clinic isn't accountable for what the body composition becomes — only for whether the scale moves.

A longevity-medicine approach treats the medication as one tool inside a measurement-driven plan. The accountability is to the underlying physiology — fat down, lean preserved, function maintained — not to the number on the bathroom scale. Highland Longevity was built around that distinction, which is part of why D Magazine recently profiled our model.